The Effect of Dalteparin, a Kind of Low Molecular Weight Heparin, on Lung Adenocarcinoma A549 Cell Line In Vitro

REFERENCES

• Klerk C. P., Smorenburg S. M., Otten H. M., et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 2005; 23: 2130–2135
   PubMed Web of Science ®Google Scholar
• Kakkar A. K., Levine M. N., Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 2004; 22: 1944–1948
   PubMed Web of Science ®Google Scholar
• Altinbas M., Coskun H. S., Er O., et al. A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2004; 2(8)1266–1271
   PubMed Web of Science ®Google Scholar
• Icli F., Akbulut H., Utkan G., et al. Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer. J Surg Oncol 2007; 95(6)507–512
   PubMed Web of Science ®Google Scholar
• Clowes A. W., Karnovsky M. J. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977; 265(5595)625–626
   PubMed Web of Science ®Google Scholar
• Guyton J. R., Rosenberg R. D., Clowes A. W., et al. Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. Circ Res 1980; 46(5)625–634
   PubMed Web of Science ®Google Scholar
• Horiuchi A., Nikaido T., Ya-Li Z., et al. Heparin inhibits proliferation of myometrial and leiomyomal smooth muscle cells through the induction of alpha-smooth muscle actin, calponin h1 and p27. Mol Hum Reprod 1999; 5(2)139–145
   PubMed Web of Science ®Google Scholar
• Coffey A. K., Karnovsky M. J. Heparin inhibits mesangial cell proliferation in habu-venom-induced glomerular injury. Am J Pathol 1985; 120(2)248–255
   PubMed Web of Science ®Google Scholar
• Johnson P. R., Armour C. L., Carey D., et al. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am J Physiol 1995; 269: L514–519, (4 Pt 1)
   PubMed Web of Science ®Google Scholar
• Erduran E., Tekelioğlu Y., Gedik Y., et al. Apoptotic effects of heparin on lymphoblasts, neutrophils, and mononuclear cells: results of a preliminary in vitro study. Am J Hemato 1999; 61(2)90–93
   PubMed Web of Science ®Google Scholar
• Margarita S. B., Abel S. A., Miguel A. P. Cell cycle deregulation in B-cell lymphomas. Blood 2003; 101(4)1220–1235
   PubMed Web of Science ®Google Scholar
• Massaque J., Polyak K. Mammalian antiproliferative signals and their targets. Curr Opin Genet Dev 1995; 5(1)91–96
   PubMedGoogle Scholar
• Slingerland J., Pagano M. Regulation of the Cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183(1)10–17
   PubMed Web of Science ®Google Scholar
• Zou X., Ray D., Aziyu A., et al. Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 2002; 16(22)2923–2934
   PubMed Web of Science ®Google Scholar
• Yu L., Quinn D. A., Garg H. G., et al. Cyclin-dependent kinase inhibitor p27Kip1, but not p21WAF1/Cip1, is required for inhibition of hypoxia-induced pulmonary hypertension and remodeling by heparin in mice. Circ Res 2005; 97(9)937–945
   PubMed Web of Science ®Google Scholar
• Collen A., Smorenburg S. M., Peters E., et al. Unfractionated and low molecular weight heparin affect fibrin structure and angiogenesis in vitro. Cancer Res 2000; 60(21)6196–6200
   PubMed Web of Science ®Google Scholar
• Nasir F. A., Patel H. K., Scully M. F. The low molecular weight heparin dalteparin sodium inhibits angiogenesis and induces apoptosis in an experimental tumor model. Blood 2003; 102(3), Abstract
   Google Scholar
• Borsig L., Wong R., Feramisco J., et al. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001; 98(6)3352–335
   PubMed Web of Science ®Google Scholar
• Ludwig R. J., Boehme B., Podda M., et al. Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res 2004; 64(8)2743–2750
   PubMed Web of Science ®Google Scholar
• Koenig A., Norgard-Sumnicht K., Linhardt R., et al. Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents. J Clin Invest 1998; 101(4)877–889
   PubMed Web of Science ®Google Scholar
• Christopherson K. W., Campbell J. J., Travers J. B., et al. Low-molecular-weight heparins inhibit CCL21-induced T cell adhesion and migration. J Pharmacol Exp Ther 2002; 302(1)290–295
   PubMed Web of Science ®Google Scholar
• Smorenburg S. M., Van N. C. J. F. The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 2001; 53(1)93–105
   Google Scholar
• Ishii T., Fujishiro M., Masudav M., et al. Effects of p27Kip1 on cell cycle status and viability in A549 lung adenocarcinoma cells. Eur Respir J 2004; 23(5)665–670
   PubMed Web of Science ®Google Scholar
• Gottlieb T. M., Oren M. p53 in growth control and neoplasia. Biochim Biophys Acta 1996; 1287(2–3)77–102
   PubMed Web of Science ®Google Scholar
• Helin K., Lees J. A., Vidal M., et al. A cDNA encoding a pRB-binding protein with properties of the transcription factor E2F. Cell 1992; 70(2)337–350
   PubMed Web of Science ®Google Scholar
• Brehm A., Miska E. A., McCance D. J., et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature (Lond) 1998; 391(6667)597–601
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13(12)1501–1512
   PubMed Web of Science ®Google Scholar
• Stavenow L., Lindblad B., Xu C. B. Unfractionated heparin and low molecular weight heparin do not inhibit the growth of proliferating human arterial smooth muscle cells in culture. Eur J Vasc Endovasc Surg 1995; 10(2)215–219
   PubMed Web of Science ®Google Scholar
• Vannucchi S., Pasquali F., Chiarugi V. P., et al. Inhibition of BC3H-1 cell growth by heparin is related to decreased mitogenic signaling. Biochem Biophys Res Commun 1990; 170(1)89–95
   PubMed Web of Science ®Google Scholar
• Yu M. K., Lee D. Y., Kim Y. S., et al. Antiangiogenic and apoptotic properties of a novel amphiphilic folate-heparin-lithocholate derivative having cellular internality for cancer therapy. Pharm Res 2007; 24(4)705–714
   PubMed Web of Science ®Google Scholar
• Lincet H., Poulain L., Remy J. S., et al. The p21 (cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett 2000; 161(1)17–26
   PubMed Web of Science ®Google Scholar
• Shibata M. A., Yoshidome K., Shibata E., et al. Suppression of mammary carcinoma growth in vitro and in vivo by inducible expression of the Cdk inhibitor p21. Cancer Gene Ther 2001; 8(1)23–35
   PubMed Web of Science ®Google Scholar
• Fotedar R., Brickner H., Saadatmandi N., et al. Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 1999; 18(24)3652–3658
   PubMed Web of Science ®Google Scholar
• Supriatno, Harada K., Hoque M. O., et al. Overexpression of p27(Kip1) induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol 2002; 38(7)730–736
   PubMed Web of Science ®Google Scholar
• Katayose Y., Kim M., Rakkar A. N., et al. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997; 57(24)5441–5445
   PubMed Web of Science ®Google Scholar
• Berry D., Lynn D. M., Sasisekharan R., et al. Poly(beta-amino ester)s promote cellular uptake of heparin and cancer cell death. Chem Biol 2004; 11(4)487–498
   PubMed Web of Science ®Google Scholar
• Erduran E., Deger O., Albayrak D., et al. In vitro investigation of the apoptotic effect of heparin on lymphoblasts by using flow cytometric DNA analysis and fluorometric caspase-3 and -8 activities. DNA Cell Biol 2007; 26(11)803–808
   PubMed Web of Science ®Google Scholar
• Erduran E., Tekelioglu Y., Gedik Y., et al. In vitro determination of the apoptotic effect of heparin on lymphoblasts using DNA analysis and measurements of Fas and Bcl-2 proteins by flow cytometry. Pediatr Hematol Oncol 2004; 21(5)383–391
   PubMed Web of Science ®Google Scholar
• Gartel A. L., Tyner A. L. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999; 246(2)280–289
   PubMed Web of Science ®Google Scholar
• Sheaff R. J., Singer J. D., Swanger J., et al. Proteasomal turnover of p21Cip1 does not require p21Cip1 ubiquitination. Mol Cell 2000; 5(2)403–410
   PubMed Web of Science ®Google Scholar
• Touitou R., Richardson J., Bose S., et al. A degradation signal located in the C-terminus of p21WAF1/ CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. Embo J 2001; 20(10)2367–2375
   PubMed Web of Science ®Google Scholar
• Maki C. G., Howley P. M. Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. Mol Cell Biol 1997; 17(1)355–363
   PubMed Web of Science ®Google Scholar
• Carrano A. C., Eytan E., Hershko A., et al. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nature Cell Biol 1999; 1(4)193–199
   PubMed Web of Science ®Google Scholar
• Fareed J., Leong W. L., Hoppensteadt D. A., et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost 2004; 30(6)703–713
   PubMed Web of Science ®Google Scholar
• Deepa P. R., Varalakshmi P. The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity. Eur J Pharmacol 2003; 478(2–3)199–205
   PubMed Web of Science ®Google Scholar